Send me real-time posts from this site at my email
Zacks

Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

Biogen, Inc. BIIB announced positive top-line data from the phase IIb CONVEY study, which evaluated its investigational non-opioid pain drug, vixotrigine, for treating pain in patients with small fiber neuropathy (“SFN”).

SFN is a form of peripheral neuropathy marked by the degeneration of small-diameter sensory fibers, including pain-producing fibers. Often characterized by severe pain in hands or feet, SFN can cause a variety of sensory and autonomic symptoms.

In the year so far, Biogen’s stock price has risen 22.4% in comparison with the industry’s 0.4% increase.


Image Source: Zacks Investment Research

The CONVEY study evaluated the efficacy and safety of vixotrigine for treating pain in patients with idiopathic or diabetes mellitus-associated SFN over a 12-week period. The study randomized the patients into three arms — two different doses of AR-15512 (200 mg or 350 mg) and placebo — dosed twice daily.

The 200 mg dose achieved the primary endpoint of statistically significant reduction in the mean average daily pain score versus placebo during the treatment period. However, the 350 mg arm failed to meet the primary endpoint. Nonetheless, the 350 mg dosage did achieve a statistically significant increase in the Patient Global Impression of Change at week 12, which is a measure of patients’ overall improvement when compared to baseline.

While the study observed numeric advantages of vixotrigine over placebo in secondary endpoints, treatment with both dosages of the drug failed to achieve statistical significance in secondary endpoints. Data from the study demonstrated that both doses of the drug were well tolerated among the participants in the study.

On the basis of the data collected from the vixotrigine program, Biogen plans to decide the potential dose administration in phase III studies. The company also plans to present detailed data from the study at a future medical meeting.

Zacks Rank & Stocks to Consider

Biogen currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector include Regeneron Pharmaceuticals REGN, Repligen Corporation RGEN and Vertex Pharmaceuticals VRTX. While Regeneron and Repligen each carry a Zacks Rank #1 (Strong Buy) at present, Vertex holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Regeneron’s earnings per share estimates for 2021 have increased from $50.00 to $53.22 in the past 60 days. The same for 2022 has risen from $40.91 to $44.84 over the same period. The stock has rallied 35.2% in the year so far.

Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 60 days. The same for 2022 has risen from $2.56 to $3.02 over the same period. The stock has rallied 56.5% in the year so far.

Vertex’s earnings per share estimates for 2021 have increased from $11.22 to $12.37 in the past 60 days. The same for 2022 has risen from $12.24 to $13.13 over the same period.


5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
 
Biogen Inc. (BIIB): Free Stock Analysis Report
 
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
 
Repligen Corporation (RGEN): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue